A recent study found that a single dose of psilocybin can induce lasting anatomical changes in the brain, potentially enhancing mental health outcomes for individuals. Conducted with 28 healthy volunteers, the research demonstrated that these structural changes remained noticeable even a month after administration.
Key findings:
- A single dose of psilocybin can induce anatomical changes in the brain.
- Changes in brain structure were still apparent a month after taking psilocybin.
- The participants received a 25mg dose of psilocybin, while a placebo group received 1mg.
- EEG results indicated a surge in brain entropy within an hour of taking psilocybin.
Prof. Robin Carhart-Harris commented on the findings, stating, “It’s remarkable to see potential anatomical brain changes one month after a single dose of any drug.” This study aligns with ongoing research into the therapeutic benefits of psychedelics, particularly regarding their potential role in mental health treatment.
In addition to this groundbreaking study, the landscape surrounding functional mushrooms is evolving. The Functional Mushroom Council, established in 2025 to unify North American growers, suppliers, and experts, recently welcomed new members including Unicorn Bags and Maine Cap N’ Stem. Companies like M2 Ingredients have introduced products such as M2Brew, a functional mushroom ingredient for brewed coffee applications.
Moreover, Fungi Perfecti has launched various product lines including Grateful Dead Gummies and Host Defense Gummies. Meanwhile, Monterey Nutra unveiled ManeFocus—a premium Lion’s Mane extract noted for its high bioavailability. This wave of innovation reflects a commitment to bridging the gap between people and fungi.